Natulan (Procarbazine Hydrochloride)

Procarbazine hydrochloride works by alkylating DNA, which creates covalent bonds that disrupt the DNA double helix. This interference blocks DNA replication and transcription, ultimately inhibiting the synthesis of DNA, RNA, and proteins required for cancer cell growth. The drug also inhibits monoamine oxidase, adding to its pharmacologic effects.

The specific dose of Natulan is individualized by the treating physician based on the patient’s cancer type, stage, body surface area, and overall health. Dosing regimens are typically defined within established chemotherapy protocols and are adjusted according to response and tolerability.

Safety data for procarbazine hydrochloride during pregnancy and lactation are limited, and the drug may pose risks to the fetus or infant. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk, and this decision should be made by a qualified healthcare professional.

To order Natulan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details and assists with any necessary import documentation.

Natulan (procarbazine) is an oral alkylating agent that differs from many others, such as cyclophosphamide, which are often administered intravenously. Procarbazine’s dual activity—including monoamine oxidase inhibition—offers a distinct toxicity profile, with common side effects like nausea and leukopenia, while sharing the core mechanism of DNA alkylation with its class.

Natulan should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Natulan is administered orally, usually in tablet form, as directed by the prescribing oncologist. The medication is taken with or without food according to the specific chemotherapy schedule, and patients should follow the exact timing and dosing instructions provided by their healthcare team.

The most serious risks associated with Natulan include severe bone‑marrow suppression leading to pancytopenia, secondary malignancies, significant liver toxicity, and rare hypersensitivity reactions such as anaphylaxis. Patients should be monitored closely for signs of infection, bleeding, jaundice, or severe allergic symptoms, and report any concerns promptly.

Natulan should not be used by individuals with known hypersensitivity to procarbazine or any component of the formulation. It is also contraindicated in patients currently receiving monoamine oxidase inhibitors, and caution is advised for those with severe hepatic impairment or uncontrolled infections.